News Lila Sciences' swollen first round, and other biofinancings AI-powered autonomous lab firm Lila Sciences upsizes its Series A to $350m, heading a bumper week for new biotech financings.
News FDA hands out first national priority vouchers to nine firms The FDA has named the first products to take advantage of its recently announced Commissioner's national priority voucher programme.
News Merck looking to rare disease deals to build health momentum Germany's Merck KGaA is looking at making further acquisitions to boost its business, with a focus on life sciences and rare diseases.
News Germany's Tubulis raises €308m for ADC pipeline Ahead of a data reveal at ESMO, Tubulis has raised €308m to help fund clinical trials of its antibody-drug conjugate for ovarian cancer.
News Can new Tukysa data drop unlock its sales potential? A phase 3 study suggests Pfizer's underperforming HER2 inhibitor Tukysa could play a role in first-line maintenance of HER2-positive breast cancer.
News Astellas suffers pancreatic cancer failure with Vyloy Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.
R&D CDMOs: Their crucial role and how to select one, with Sigma ... Sigma Mostafa, CSO at KBI BioPharma, discusses the role of CDMOs and the important factors companies should consider when selecting one.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.